Bluebird’s Fast Lyfgenia Launch Was A Year And A Half In The Making

Zynteglo Build Gives Firm A Leg Up In Sickle Cell Disease

 
• By Mandy Jackson
  
Generate a summary of this article
Listen to this article
Beta

The company said when Zynteglo was approved for beta-thalassemia that its launch would lay the groundwork for its sickle cell gene therapy Lyfgenia, and the strategy is paying off so far with a fast ramp-up.

DNA helix 3D illustration. Mutations under microscope. Decoding genome.
Bluebird's sickle cell gene therapy Lyfgenia launched in January • Source: Shutterstock

Bluebird bio inc.’s sickle cell disease gene therapy Lyfgenia (lovotibeglogene autotemcel) won US Food and Drug Administration approval on the same day in December as Vertex Pharmaceuticals Incorporated/CRISPR Therapeutics AG’s competing gene-editing medicine Casgevy (exagamglogene autotemcel), but as of the J.P. Morgan Healthcare Conference a month later bluebird’s product is in the lead in terms of qualified treatment centers (QTCs) ready to administer the drug and the number of patient lives covered by payers that have agreed to reimburse Lyfgenia’s multimillion-dollar cost.

Key Takeaways

  • Bluebird’s Lyfgenia launch to date has resulted in 35 qualified treatment centers ready to administer the sickle cell gene therapy in the US versus nine centers ready to administer Vertex/CRISPR’s gene-editing medicine.

The company said when it won FDA approval for its beta-thalassemia gene therapy Zynteglo (betibeglogene autotemcel) in August 2022 that...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Gene Therapies

Scrip Asks…What Does 2024 Hold For Biopharma? Part 6: Therapeutic Area Advances KOSH SANDBOX

 
• By Kosh Naran

More than 100 biopharma executives and experts told Scrip their predictions for therapeutic area advances in the coming year. The recent commercial success of GLP-1s in diabetes and obesity and their potential in further disease areas fuelled excitement around the metabolic space. Expectations were also positive in neurology following the launch of Leqembi for Alzheimer’s disease in 2023, while the multiple opportunities to improve cancer treatment kept oncology top of the pile overall.

Quick Listen: Scrip's Five Must-Know Things

 
• By Ian Haydock

In this week's podcast edition of Five Must-Know Things: Merck & Co. steps into CD19 bispecific space; gene therapy patients rise, but slowly; Madrigal’s Rezdiffra plans; Korean biopharma financing recovering?; and approvals to watch out for in Q3.

Gene Therapy Patient Pipeline Builds, But Slowly, In Q2

 
• By Jessica Merrill

Bluebird, Vertex and Sarepta are starting to see some commercial gene therapy traction and expect momentum to pick up in the second half, while hemophilia remains a challenging area. 

More from Advanced Therapies

spo

Akash test for clone

Test article to check the clone issue

Live test

 
• By Mary Jo Laffler

Progress Or Hype? A Decade Of Cell Therapy In Japan

 
• By Lisa Takagi

After 10 years of promised investment following its Nobel Prize for iPS cell research, Japan is cautiously narrowing regulations around the conditional approval of cell therapies and cutting some reimbursement prices. Commercial success remains mixed and some products have been withdrawn from the market.